This occurred when travelers recorded that more doses of

the antimalarial treatment had been taken than had been prescribed by the investigator. It was not possible to go back to the traveler to obtain the reasons for this. Of 252 travelers consented into the study, 251 completed the pre-travel questionnaire (intention-to-treat). Of these, 185 completed the pre- and post-travel questionnaires and these make up the total analyzed sample. No differences of note were seen between the characteristics of those who completed both questionnaires and those who only completed the pre-travel questionnaire. The number of travelers taking each of the medications together with their age and sex Palbociclib are shown in Table 1. The distribution of males and females between the groups was similar, but there were statistically significant differences in mean age, with travelers in the Mfl and At+Pro groups tending to selleck chemical be older than in the Dxy group. The reasons for travel were identified as: business 28%, holiday 59%, visit friends/relatives 8%, and other 5%. The median time of travel was 14 days (inter-quartile range: 9–20 d). Thirty-six percent of the travelers had previously taken one or more of the antimalarials being studied. Adherence analyzed

as the number of tablets reported as taken (as a percentage of prescribed), both overall, which includes pre-, during, and post-travel, (primary end point) and for each period separately are shown in Table 2. Statistically significant differences (at the 5% level) in median percentage adherence were seen between the At+Pro and Dxy groups for overall and post-travel Thiamet G adherence, with travelers taking At+Pro having higher levels of adherence. Median percentage adherence in the Mfl group was numerically lower than for either At+Pro or Dxy overall, pre-, and during travel, and numerically lower than for At+Pro post-travel. Adherence analyzed as the proportion of travelers, who reported taking all their medication from the categorical adherence

scale, is shown in Table 3. A higher percentage of travelers in the At+Pro group compared with the Dxy group stated that they took all their medication overall, during, and post-travel, with statistical significance for overall and post-travel. Categorical adherence in the Mfl group was numerically similar or better than for At+Pro at all stages of travel. Calculating odds ratios, travelers taking At+Pro were 2.59 times more likely to take all post-travel medication compared with Dxy (95% CI 1.27–5.26, p = 0.008) and 2.6 times more likely to take ≥80% of post-travel medication (95% CI 1.29–5.25, p = 0.007). Characteristics such as age or sex did not appear to influence whether travelers reported taking at least 80% or less than 80% of prescribed medication. Factors considered highly important for their choice of antimalarial by travelers completing the pre-travel questionnaire and investigators are shown in Figure 1.